Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
Open accessAbstract
Objective Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10-year coronary heart disease (CHD) risk calculated by the Framingham Heart Study formula.Method Change in 10-year risk for CHD was compared between treatment groups in 1125 patients followed for 18 months or until treatment discontinuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial.Results The covariate-adjusted mean change in 10-year CHD risk differed significantly between treatments. Olanzapine was associated with a 0.5% (SE 0.3) increase and quetiapine, a 0.3% (SE 0.3) increase; whereas risk decreased in patients treated with perphenazine, -0.5% (SE 0.3), risperidone, -0.6% (SE 0.3), and ziprasidone -0.6% (SE 0.4). The difference in 10-year CHD risk between olanzapine and risperidone was statistically significant (p=0.004). Differences in estimated 10-year CHD risk between drugs were most marked in the tertile of subjects with a baseline CHD risk of at least 10%. Among individual CHD risk factors used in the Framingham formula, only total and HDL cholesterol levels differed between treatments.Conclusions These results indicate that the impact on 10-year CHD risk differs significantly between antipsychotic agents, with olanzapine producing the largest elevation in CHD risk of the agents studied in CATIE.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Daumit et al. 2008 found treatment with olanzapine and quetiapine was associated with higher long-term risk of cardiovascular disease than treatment with perphenazin, risperidone, and ziprasidone.
“Daumit et al. (2008) analyzed changes in 10-year coronary heart disease risk estimates during the 18-month CATIE trial by antipsychotic treatment, and they found that treatment with olanzapine and quetiapine was associated with a higher long-term risk of cardiovascular disease than was treatment with perphenazin, risperidone, and ziprasidone.”
From Excess early mortality in schizophrenia. (2014) · cites this paper as Daumit et al. 2008
Several factors contribute to the early and frequent development of cardiovascular disease in this population, including genetic vulnerability, metabolic adverse effects of antipsychotics, insufficient treatment of somatic comorbidity, and unhealthy lifestyle.
“Several factors contribute to the early and frequent development of cardiovascular disease in this population, including genetic vulnerability 5 , metabolic adverse effects of antipsychotics 6,7 , insufficient treatment of somatic comorbidity 8 , and unhealthy lifestyle 9 .”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581 · see citing works
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · see citing works
Self-citationAntipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · see citing works
D'Agostino, R. B., Grundy, S., Sullivan, L. M., Wilson, P., & for the CHD Risk Prediction Group (2001) · JAMA · doi:10.1001/jama.286.2.180 · Cited by 2,108 · see citing works
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · see citing works
(1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410020010002 · Cited by 1,960 · see citing works
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554 · see citing works
(2006) · Europe PMC (PubMed Central) · Cited by 1,299 · see citing works
Mcevoy, J., Meyer, J., Goff, D., Nasrallah, H., Davis, S., Sullivan, L., Meltzer, H., Hsiao, J. K., Stroup, T., & Lieberman, J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,220 · see citing works
Self-citationConsensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., LAUGHREN, T. P., & Katz, R. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204 · see citing works
Excess mortality of schizophrenia: A meta-analysis
Brown, S. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.502 · Cited by 869 · see citing works
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N. H., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812 · see citing works
Self-citationMortality and causes of death in schizophrenia in Stockholm County, Sweden
Ösby, U., Correia, N., Brandt, L., Ekbom, A., & Sparén, P. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00191-7 · Cited by 679 · see citing works
Stroup, T., Mcevoy, J., Swartz, M., Byerly, M., Glick, I., Cañive, J., McGee, M., Simpson, G., Stevens, M., & Lieberman, J. (2003) · Schizophrenia bulletin · doi:10.1093/oxfordjournals.schbul.a006986 · Cited by 647 · see citing works
Self-citationCigarette smoking in schizophrenia: relationship to psychopathology and medication side effects
GOFF, D. C., Henderson, D. C., & Amico, E. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1189 · Cited by 580 · see citing works
Self-citationGoff, D. C., Sullivan, L. M., McEvoy, J. P., Meyer, J. M., Nasrallah, H. A., Daumit, G. L., Lamberti, S., D'Agostino, R. B., Stroup, T. S., Davis, S., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.08.010 · Cited by 528 · see citing works
Self-citationDiet, smoking and cardiovascular risk in people with schizophrenia
McCreadie, R. G., & Scottish Schizophrenia Lifestyle Group (2003) · The British Journal of Psychiatry · doi:10.1192/bjp.183.6.534 · Cited by 494 · see citing works
The effects of antipsychotic therapy on serum lipids: a comprehensive review
Meyer, J. M., & Koro, C. E. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.014 · Cited by 407 · see citing works
Self-citationMortality and medical comorbidity among psychiatric patients: a review
Felker, B. L., Yazel, J. J., & Short, D. D. (1996) · Psychiatric Services · doi:10.1176/ps.47.12.1356 · Cited by 395 · see citing works
Diet, smoking and cardiovascular risk in people with schizophrenia
McCreadie, R. G., & Scottish Schizophrenia Lifestyle Group (2003) · The British Journal of Psychiatry · doi:10.1192/03-162 · Cited by 392 · see citing works
The Distribution of Body Mass Index Among Individuals With and Without Schizophrenia
Allison, D. B., Fontaine, K. R., Heo, M., Mentore, J. L., Cappelleri, J. C., Chandler, L. P., Weiden, P. J., & Cheskin, L. J. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0402 · Cited by 390 · see citing works
Lohr, J. B., & FLYNN, K. (1992) · Schizophrenia Research · doi:10.1016/0920-9964(92)90024-y · Cited by 340 · see citing works
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315 · see citing works
Physical Activity Patterns in Adults With Severe Mental Illness
Daumit, G. L., Goldberg, R. W., Anthony, C. B., Dickerson, F., Brown, C. H., Kreyenbuhl, J. A., Wohlheiter, K. A., & Dixon, L. B. (2005) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000180737.85895.60 · Cited by 306 · see citing works
Self-citationThe Effects of Novel Antipsychotics on Glucose and Lipid Levels
Wirshing, D. A., A., J. A. J., Meng, L. R., Ballon, J. S., Marder, S. R., & Wirshing, W. C. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1002 · Cited by 294 · see citing works
Meyer, J. M., Davis, V. G., GOFF, D. C., McEvoy, J. P., Nasrallah, H. A., Thomas, S., Rosenheck, R. A., Daumit, G. L., Hsiao, J., Swartz, M. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.487 · Cited by 286 · see citing works
Self-citationMeyer, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0509 · Cited by 267 · see citing works
Self-citationDesign and implementation of a nutrition and physical activity curriculum for child care settings.
Dunn, C., Thomas, C., Ward, D. S., Pegram, L., Webber, K., & Cullitan, C. (2006) · Europe PMC (PubMed Central) · Cited by 186 · see citing works
Nutritional Assessment of Patients With Schizophrenia: A Preliminary Study
Strassnig, M., Brar, J. S., & Ganguli, R. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007013 · Cited by 175 · see citing works
Novel Antipsychotics and Severe Hyperlipidemia
Meyer, J. M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00003 · Cited by 170 · see citing works
Self-citationImprovement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone
Weiden, P. J., Daniel, D. G., Simpson, G. M., & Romano, S. J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095347.32154.08 · Cited by 124 · see citing works
Kreyenbuhl, J. A., Dickerson, F., Medoff, D. R., Brown, C. H., Goldberg, R. W., Fang, L., Wohlheiter, K. A., Mittal, L. P., & Dixon, L. B. (2006) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000221177.51089.7d · Cited by 109 · see citing works
A Study of Quetiapine: Efficacy and Tolerability in Psychotic Adolescents
Shaw, J. A., Lewis, J. E., Pascal, S., Sharma, R., Rodriguez, R. A., Guillen, R., & Pupo-Guillen, M. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454601317261591 · Cited by 108 · see citing works
Daumit, G., Clark, J., Steinwachs, D., Graham, C. M., Lehman, A., & Ford, D. (2003) · Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000100923.20188.2d · Cited by 104 · see citing works
Self-citationThe Apparent Effects of Ziprasidone on Plasma Lipids and Glucose
Kingsbury, S. J., Fayek, M., Trufasiu, D., Zada, J., & Simpson, G. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0507 · Cited by 73 · see citing works
Atmaca, M., Kuloğlu, M., Tezcan, E., Geçici, Ö., & Üstündağ, B. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00305-5 · Cited by 56 · see citing works
The metabolic syndrome and schizophrenia: A review
Meyer, J. M., Koro, C. E., & L'Italien, G. J. (2005) · International Review of Psychiatry · doi:10.1080/09540260500071798 · Cited by 55 · see citing works
Self-citationA psychiatric rehabilitation approach to weight loss.
Brown, C. E., Goetz, J. R., Sciver, A. R. V., Sullivan, D. K., & Hamera, E. K. (2006) · Psychiatric Rehabilitation Journal · doi:10.2975/29.2006.267.273 · Cited by 44 · see citing works
HALOPERIDOL, CLOPENTHIXOL, AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA
Serafetinides, E. A., COLLINS, S., & Clark, M. L. (1972) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197201000-00005 · Cited by 41 · see citing works
HALOPERIDOL, CLOPENTHIXOL, AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA
Serafetinides, E. A., WILLIS, D., & Clark, M. L. (1972) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197211000-00010 · Cited by 40 · see citing works
Lipids and apolipoproteins in patients treated with major tranquilizers
Sasaki, J., FUNAKOSHI, M., & Arakawa, K. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.113 · Cited by 27 · see citing works
Antidepressants and Risk of Cancer: A Case of Misguided Associations and Priorities
Theoharides, T. C., & Konstantinidou, A. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00001 · Cited by 23 · see citing works
Ellsworth, D. L., O'Dowd, S. C., Salami, B., Hochberg, A. M., Vernalis, M., Marshall, D. A., Morris, J. A., & Somiari, R. I. (2004) · Preventive Cardiology · doi:10.1111/j.1520-037x.2004.3332.x · Cited by 16 · see citing works
Change in Framingham Risk Score in Patients With Schizophrenia
del Valle, M. C., Loebel, A. D., Murray, S., Yang, R., Harrison, D. J., & Cuffel, B. J. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0602 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Meyer JM Davis VG Change in Metabolic Syndrome Status and Associated Parameters in the CATIE Schizophrenia Trial Phase 1 Schizophr Res (in press) PMC3673564 18258416
Cited by
Sorted by citations
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · see citing works
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · see citing works
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · see citing works
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · see citing works
Excess early mortality in schizophrenia.
Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153657 · Cited by 913 · see citing works
Nordentoft, M., Wahlbeck, K., Hällgren, J., Westman, J., Ösby, U., Alinaghizadeh, H., Gissler, M., & Laursen, T. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055176 · Cited by 778 · see citing works
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 679 · see citing works
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 261 · see citing works
Ziprasidone versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Hunger, H., Schwarz, S., Bhoopathi, P. S., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006627.pub2 · Cited by 241 · see citing works
Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort
Flowers, S. A., Evans, S. J., Ward, K. M., McInnis, M. G., & Ellingrod, V. L. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1890 · Cited by 235 · see citing works
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224 · see citing works
Teff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H.-L., & Rickels, K. (2013) · Diabetes · doi:10.2337/db13-0430 · Cited by 195 · see citing works
Janssen, E. M., McGinty, E. E., Azrin, S. T., Juliano‐Bult, D., & Daumit, G. L. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.03.004 · Cited by 195 · see citing works
Self-citationDurgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Németh, G., & Laszlovszky, I. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.11.041 · Cited by 192 · see citing works
Metabolic syndrome with the atypical antipsychotics
Pramyothin, P., & Khaodhiar, L. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833de61c · Cited by 173 · see citing works
Speyer, H., Christian Brix Nørgaard, H., Birk, M., Karlsen, M., Storch Jakobsen, A., Pedersen, K., Hjorthøj, C., Pisinger, C., Gluud, C., Mors, O., et al. (2016) · World Psychiatry · doi:10.1002/wps.20318 · Cited by 153 · see citing works
Jarskog, L. F., Hamer, R. M., Catellier, D. J., Stewart, D. D., LaVange, L., Ray, N., Golden, L. H., Lieberman, J. A., Stroup, T. S., & for the METS Investigators (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12010127 · Cited by 145 · see citing works
Self-citationDiabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review
Mangurian, C. V., Newcomer, J. W., Modlin, C., & Schillinger, D. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3712-4 · Cited by 116 · see citing works
Myint, P. K., Fox, C., Kwok, C. S., Luben, R., Wareham, N. J., & Khaw, K. (2014) · Age and Ageing · doi:10.1093/ageing/afu185 · Cited by 109 · see citing works
Ventriglio, A., Gentile, A., Stella, E., & Bellomo, A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00297 · Cited by 108 · see citing works
Flowers, S. A., Baxter, N. T., Ward, K. M., Kraal, A. Z., McInnis, M. G., Schmidt, T. M., & Ellingrod, V. L. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2214 · Cited by 100 · see citing works
Bly, M. J., Taylor, S. F., Dalack, G. W., Pop‐Busui, R., Burghardt, K. J., Evans, S. J., McInnis, M. G., Grove, T. B., Brook, R. D., Zöllner, S. K., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12160 · Cited by 100 · see citing works
Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men
Fountaine, R. J., Taylor, A. E., Mancuso, J. P., Greenway, F. L., Byerley, L. O., Smith, S. R., Most, M. M., & Fryburg, D. A. (2010) · Obesity · doi:10.1038/oby.2010.6 · Cited by 99 · see citing works
Laursen, T. M., & Nordentoft, M. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.04.027 · Cited by 93 · see citing works
Review: Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?
Wildgust, H. J., & Beary, M. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810384639 · Cited by 93 · see citing works
The association between weight change and symptom reduction in the CATIE schizophrenia trial
Hermes, E. D. A., Nasrallah, H. A., Davis, V. G., Meyer, J. M., McEvoy, J. P., GOFF, D. C., Thomas, S., Stroup, T. S., Swartz, M. S., Lieberman, J. A., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.022 · Cited by 86 · see citing works
Self-citationSchizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models
Samsom, J. N., & Wong, A. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00013 · Cited by 82 · see citing works
Sharma, R., Wigginton, B., Meurk, C., Ford, P. J., & GARTNER, C. E. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14010007 · Cited by 79 · see citing works
Antipsychotics cardiotoxicity: What's known and what's next
Li, X., Tang, X.-R., & Li, L. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i10.736 · Cited by 77 · see citing works
Kiviniemi, M., Suvisaari, J., Koivumaa-Honkanen, H. T., Häkkinen, U., Isohanni, M. K., & Hakko, H. H. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.043 · Cited by 77 · see citing works
Risk of weight gain for specific antipsychotic drugs: a meta-analysis
Spertus, J. V., Horvitz-Lennon, M. V., Abing, H. K., & Normand, S. T. (2018) · Schizophrenia · doi:10.1038/s41537-018-0053-9 · Cited by 77 · see citing works
Cardiovascular effects of psychotic illnesses and antipsychotic therapy
Howell, S., Yarovova, E., Khwanda, A., & Rosen, S. D. (2019) · Heart · doi:10.1136/heartjnl-2017-312107 · Cited by 74 · see citing works
The challenge of reducing smoking in people with serious mental illness
Sharma, R., GARTNER, C. E., & Hall, W. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30228-4 · Cited by 70 · see citing works
Cardiovascular aspects of antipsychotics
Raedler, T. J. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833f46c9 · Cited by 89 · see citing works
Verhaegen, A. A., & Gaal, L. F. V. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0719-6 · Cited by 68 · see citing works
Quetiapine versus other atypical antipsychotics for schizophrenia
Asmal, L., Flegar, S. J., Wang, J., Rummel‐Kluge, C., Komossa, K., & Leucht, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub3 · Cited by 67 · see citing works
Aschbrenner, K. A., Carpenter-Song, E. A., Mueser, K. T., Kinney, A., Pratt, S. I., & Bartels, S. J. (2012) · Community Mental Health Journal · doi:10.1007/s10597-012-9552-8 · Cited by 64 · see citing works
Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making
Foussias, G., & Remington, G. J. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500302 · Cited by 59 · see citing works
Bushe, C., Bradley, A. J., Doshi, S. M., & Karagianis, J. L. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02224.x · Cited by 56 · see citing works
Jin, H., Folsom, D. P., Sasaki, A., Mudaliar, S. R. D., Henry, R. R., Torres, M., Golshan, S., Glorioso, D., & Jeste, D. V. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.10.029 · Cited by 55 · see citing works
Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53 · see citing works
Vergara-Rodriguez, P., Vibhakar, S., & Watts, J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.004 · Cited by 53 · see citing works
Skrede, S., Martins, L., Berge, R. K., Steen, V. M., López, M., & Fernø, J. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000862 · Cited by 53 · see citing works
Jin, H., Shih, P.-A. B., Golshan, S., Mudaliar, S. R. D., Henry, R. R., Glorioso, D., Arndt, S. V., KRAEMER, H. C., & Jeste, D. V. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08001 · Cited by 53 · see citing works
A review of the safety and tolerability of aripiprazole
Pae, C. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902835493 · Cited by 51 · see citing works
Newcomer, J. W., Weiden, P. J., & Buchanan, R. W. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12028ah1 · Cited by 51 · see citing works
Stanley, S. H., & Laugharne, J. D. E. (2013) · International Journal of Behavioral Medicine · doi:10.1007/s12529-013-9298-x · Cited by 51 · see citing works
Stanley, S. H., & Laugharne, J. D. E. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.614591 · Cited by 51 · see citing works
Higher mortality and years of potential life lost of suicide in patients with schizophrenia
Ko, Y. S., Tsai, H.-C., Chi, M. H., Su, C., Lee, I. H., Chen, P. S., Chen, K. C., & Yang, Y. K. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.09.038 · Cited by 54 · see citing works
The atypical antipsychotic quetiapine induces hyperlipidemia by activating intestinal PXR signaling
Meng, Z., Gwag, T., Sui, Y., Park, S., Zhou, X., & Zhou, C. (2019) · JCI Insight · doi:10.1172/jci.insight.125657 · Cited by 52 · see citing works
Kurdyak, P. A., Vigod, S. N., Calzavara, A. J., & Wodchis, W. P. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.09.003 · Cited by 49 · see citing works
Neural Correlates of Weight Gain With Olanzapine
Mathews, J., Newcomer, J. W., Mathews, J. R., Fales, C. L., Pierce, K. J., Akers, B., Marcu, I., & Barch, D. M. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.934 · Cited by 50 · see citing works
Use of 12-Month Renal Function and Baseline Clinical Factors to Predict Long-Term Graft Survival
Schnitzler, M. A., Lentine, K. L., Axelrod, D. A., Gheorghian, A., You, M., Kalsekar, A., & L'Italien, G. J. (2011) · Transplantation · doi:10.1097/tp.0b013e31823ec02a · Cited by 46 · see citing works
Boreu, Q. F., Martin, M., Flores‐Mateo, G., Zabaleta‐del‐Olmo, E., Ayerbe, L., López, M. P.-P., Martín‐Lopez, L. M., Montes‐Hidalgo, J., & Violán, C. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0833-6 · Cited by 46 · see citing works
DIABETIC KETOACIDOSIS ASSOCIATED WITH ANTIPSYCHOTIC DRUGS: CASE REPORTS AND A REVIEW OF LITERATURE
Vuk, A., Kuzman, M. R., Baretić, M., & Osvatić, M. M. (2017) · Psychiatria Danubina · doi:10.24869/psyd.2017.121 · Cited by 46 · see citing works
Furiak, N. M., Ascher‐Svanum, H., Klein, R. W., Smolen, L. J., Lawson, A. H., Conley, R. R., & Culler, S. D. (2009) · Cost Effectiveness and Resource Allocation · doi:10.1186/1478-7547-7-4 · Cited by 45 · see citing works
Antipsychotic drug treatment for elderly people with late-onset schizophrenia
Essali, A., & Ali, G. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004162.pub2 · Cited by 45 · see citing works
Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients
Lappin, J., Wijaya, M., Watkins, A., Morell, R., Teasdale, S. B., Lederman, O., Rosenbaum, S., Dick, S., Ward, P. B., & Curtis, J. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.035 · Cited by 45 · see citing works
Rodrigues, M., Wiener, J. C., Stranges, S., Ryan, B. L., & Anderson, K. K. (2020) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2020.110315 · Cited by 43 · see citing works
Psychological Co-morbidities of Physical Illness
Pagoto, S. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0029-6 · Cited by 42 · see citing works
The unchanging mortality gap for people with schizophrenia.
Chwastiak, L. A., & Tek, C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61072-2 · Cited by 41 · see citing works
Dregan, A., McNeill, A., Gaughran, F., Jones, P. B., Bazley, A., Cross, S., Lillywhite, K., Armstrong, D., Smith, S., Osborn, D. P. J., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230674 · Cited by 41 · see citing works
Fernø, J., Ersland, K. M., Duus, I. H., González‐García, I., Fossan, K. O., Berge, R. K., Steen, V. M., & Skrede, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.03.002 · Cited by 40 · see citing works
McNamara, R. K., Jandacek, R. J., Rider, T., Tso, P., Cole-Strauss, A., & Lipton, J. W. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.03.006 · Cited by 40 · see citing works
Stroup, T. S., Byerly, M. J., Nasrallah, H. A., Ray, N., Khan, A. Y., Lamberti, J. S., Glick, I. D., Steinbook, R. M., McEvoy, J. P., & Hamer, R. M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.013 · Cited by 39 · see citing works
Self-citationStanley, S. H., & Laugharne, J. D. E. (2011) · Australian Journal of Primary Health · doi:10.1071/py11045 · Cited by 38 · see citing works
Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism
Verhaegen, A. A., & Gaal, L. F. V. (2019) · Europe PMC (PubMed Central) · Cited by 38 · see citing works
Binder, M. D., Mittoux, A., He, Y., & Peuskens, J. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0142-x · Cited by 38 · see citing works
Management of serious cardiac adverse effects of antipsychotic medications
Stoner, S. C. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.11.246 · Cited by 37 · see citing works
Shertzer, H. G., Kendig, E. L., Nasrallah, H. A., Johansson, E., & Genter, M. B. (2010) · International Journal of Obesity · doi:10.1038/ijo.2009.291 · Cited by 37 · see citing works
Self-citationAntipsychotics and Metabolics in the Post-CATIE Era
Meyer, J. M. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_45 · Cited by 36 · see citing works
Self-citationPersistence of racial disparities in prescription of first-generation antipsychotics in the USA
Cook, T. B., Reeves, G. M., Teufel, J. A., & Postolache, T. T. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3819 · Cited by 35 · see citing works
The University of North Carolina at Chapel Hill University Libraries (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt170 · Cited by 46 · see citing works
Can Exercise Increase Fitness and Reduce Weight in Patients with Schizophrenia and Depression?
Krogh, J., Speyer, H., Nørgaard, H. C. B., Moltke, A., & Nordentoft, M. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00089 · Cited by 34 · see citing works
Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia
Tay, Y. H., Nurjono, M., & Lee, J. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.03.023 · Cited by 34 · see citing works
Yarborough, B. J. H., Leo, M. C., Stumbo, S. P., Perrin, N., & Green, C. A. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-238 · Cited by 33 · see citing works
Lee, N. Y., Kim, S. H., Cho, B., Lee, Y. J., Chang, J. S., Kang, U. G., Kim, Y. S., & Ahn, Y. M. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.029 · Cited by 33 · see citing works
Gohlke, J. M. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00062 · Cited by 32 · see citing works
Improving the physical health of long-term psychiatric inpatients
Hjorth, P., Davidsen, A., Kilian, R., Eriksen, S. P., Jensen, S. O. W., Sørensen, H. Ø., & Munk-Jørgensen, P. (2014) · Australian and New Zealand journal of psychiatry (Print) · doi:10.1177/0004867414533011 · Cited by 31 · see citing works
Bushe, C., Sniadecki, J. L., Bradley, A., & Hoffmann, V. P. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108101783 · Cited by 31 · see citing works
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia
Nasrallah, H. A., Aquila, R., Du, Y., Stanford, A. D., Claxton, A., & Weiden, P. J. (2018) · CNS Spectrums · doi:10.1017/s1092852918001104 · Cited by 29 · see citing works
Self-citationBeauchemin, M., Geguchadze, R., Guntur, A. R., Nevola, K. T., Le, P. T., Barlow, D. J., Rue, M., Vary, C., Lary, C. W., Motyl, K. J., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104589 · Cited by 30 · see citing works
Green, C. A., Yarborough, B. J. H., Leo, M. C., Stumbo, S. P., Perrin, N., Nichols, G. A., & Stevens, V. J. (2015) · Obesity · doi:10.1002/oby.21205 · Cited by 28 · see citing works
Regional Differences in Five-Year Mortality After a First Episode of Schizophrenia in Finland
Kiviniemi, M., Suvisaari, J., Pirkola, S. P., Häkkinen, U., Isohanni, M. K., & Hakko, H. H. (2010) · Psychiatric Services · doi:10.1176/ps.2010.61.3.272 · Cited by 30 · see citing works
Stürup, A. E., Jensen, H., Dolmer, S., Birk, M., Albert, N., Nielsen, M., Hjorthøj, C. R., Eplov, L. F., Ebdrup, B. H., Mors, O. N., et al. (2017) · Trials · doi:10.1186/s13063-017-2172-4 · Cited by 28 · see citing works
Shi, L., Ascher‐Svanum, H., Chiang, Y., Zhao, Y., Fonseca, V. A., & Winstead, D. K. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-80 · Cited by 28 · see citing works
Tomasik, J., Schwarz, E., Lago, S. G., Rothermundt, M., Leweke, F. M., van Beveren, N. J. M., Guest, P. C., Rahmoune, H., Steiner, J. H., & Bahn, S. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.10.019 · Cited by 27 · see citing works
Oh, J., Nam, H., Park, S. M., Chae, J., & Kim, T. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.01.006 · Cited by 27 · see citing works
Weinmann, S., & Aderhold, V. (2009) · Psychosis · doi:10.1080/17522430903501999 · Cited by 27 · see citing works
Beyaert, M. G. R., Daya, R. P., Dyck, B. A., Johnson, R. L., & Mishra, R. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.010 · Cited by 28 · see citing works
Cardiovascular disease and diabetes in people with severe mental illness
Binder, M. D., Dekker, J. M., Wood, D. A., Kahl, K. G., & Möller, H. (2009) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/s2173-5050(09)70031-7 · Cited by 27 · see citing works
A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
Bodén, R., Edman, Reutfors, J., Östenson, C., & Ösby (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s40554 · Cited by 27 · see citing works
Parameswaran, S., Chang, C. H., Swenson, A., Shumway, M., Olfson, M., & Mangurian, C. V. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.08.031 · Cited by 26 · see citing works
Szczepanska‐Sadowska, E. K., Wsół, A., Cudnoch‐Jędrzejewska, A., Czarzasta, K., & Żera, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040908 · Cited by 26 · see citing works
McLean, G., Martin, J. L., Martin, D. J., Guthrie, B., Mercer, S. W., & Smıth, D. J. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.07.022 · Cited by 25 · see citing works
Use of Antipsychotics and Risk of Cerebrovascular Events in Schizophrenic Patients
Hsieh, P.-H., Hsiao, F., Gau, S. S., & Gau, C. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182900dfe · Cited by 26 · see citing works
Warren, K. R., Ball, M. P., Feldman, S. M., Liu, F., McMahon, R. P., & Kelly, D. L. (2010) · Biological Research For Nursing · doi:10.1177/1099800410393272 · Cited by 23 · see citing works
Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave
Hert, M. D., Dekker, J. M., Wood, D. A., Kahl, K. G., & Möller, H. (2009) · Revista de Psiquiatría y Salud Mental · doi:10.1016/s1888-9891(09)70714-1 · Cited by 23 · see citing works
Protopopová, D., Masopust, J., Malý, R., Vališ, M., & Bažant, J. (2012) · PubMed · Cited by 23 · see citing works
Heald, A., Martin, J. L., Payton, T., Khalid, L., Anderson, S., Narayanan, R., de Hert, M., Yung, A., & Livingston, M. (2017) · Australian and New Zealand journal of psychiatry (Print) · doi:10.1177/0004867415625817 · Cited by 26 · see citing works
- Authors
- Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., & Lieberman, J. A.
- Affiliations
- Johns Hopkins University (US)
- Harvard University (US)
- University of California San Diego (US)
- Bank of America (US)
- University of Cincinnati (US)
- Duke University (US)
- Yale University (US)
- National Institutes of Health (US)
- University of North Carolina at Chapel Hill (US)
- Columbia University (US)
- Corresponding author
- Daumit, Gail L.
- ORCID
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 105
- Issue
- 1-3
- Pages
- 175-187
- ISSN
- 0920-9964 (ISSN-L)
- PMC
- PMC2614656
- OpenAlex
- W2107325590
- Cited by
- 223
- References
- 44
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 2 · 2022: 6 · 2021: 9 · 2020: 6 · 2019: 11 · 2018: 11 · 2017: 13 · 2016: 10 · 2015: 20 · 2014: 16 · 2013: 24 · 2012: 20
- FWCI
- 14.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (1MH900001)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- antipsychotic drugs, coronary heart disease risk
- MeSH terms
- Adult, Coronary Disease, Female, Follow-Up Studies, Humans, Hypertension, Longitudinal Studies, Male, Obesity, Patient Dropouts, Risk Factors, Schizophrenia, Schizophrenic Psychology, Smoking, Antipsychotic Agents, Weight Gain, Comorbidity, Treatment Outcome, Outcome Assessment, Health Care, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
